In-vivo evidence of systemic endothelial vascular dysfunction in COVID-19.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 12 2021
Historique:
received: 25 07 2021
revised: 30 09 2021
accepted: 22 10 2021
pubmed: 28 10 2021
medline: 26 11 2021
entrez: 27 10 2021
Statut: ppublish

Résumé

Endothelial dysfunction is one of the underlying mechanisms to vascular and cardiac complications in patients with COVID-19. We sought to investigate the systemic vascular endothelial function and its temporal changes in COVID-19 patients from a non-invasive approach with reactive hyperemia peripheral arterial tonometry (PAT). This is a prospective, observational, case-control and blinded study. The population was comprised by 3 groups: patients investigated during acute COVID-19 (group 1), patients investigated during past COVID-19 (group 2), and controls 1:1 matched to COVID-19 patients by demographics and cardiovascular risk factors (group 3). The natural logarithmic scaled reactive hyperemia index (LnRHI), a measure of endothelium-mediated dilation of peripheral arteries, was obtained in all the participants and compared between study groups. 144 participants were enrolled (72 COVID-19 patients and 72 matched controls). Median time from COVID-19 symptoms to PAT assessment was 9.5 and 101.5 days in groups 1 and 2, respectively. LnRHI was significantly lower in group 2 compared to both group 1 and controls (0.53 ± 0.23 group 2 vs. 0.72 ± 0.26 group 1, p = 0.0043; and 0.79 ± 0.23 in group 3, p < 0.0001). In addition, within group 1, it was observed a markedly decrease in LnRHI from acute COVID-19 to post infection stage (0.73 ± 0.23 vs. 0.42 ± 0.26, p = 0.0042). This study suggests a deleterious effect of SARS-CoV-2 infection on systemic vascular endothelial function. These findings open new venues to investigate the clinical implication and prognostic role of vascular endothelial dysfunction in COVID-19 patients and post-COVID syndrome using non-invasive techniques.

Sections du résumé

BACKGROUND
Endothelial dysfunction is one of the underlying mechanisms to vascular and cardiac complications in patients with COVID-19. We sought to investigate the systemic vascular endothelial function and its temporal changes in COVID-19 patients from a non-invasive approach with reactive hyperemia peripheral arterial tonometry (PAT).
METHODS
This is a prospective, observational, case-control and blinded study. The population was comprised by 3 groups: patients investigated during acute COVID-19 (group 1), patients investigated during past COVID-19 (group 2), and controls 1:1 matched to COVID-19 patients by demographics and cardiovascular risk factors (group 3). The natural logarithmic scaled reactive hyperemia index (LnRHI), a measure of endothelium-mediated dilation of peripheral arteries, was obtained in all the participants and compared between study groups.
RESULTS
144 participants were enrolled (72 COVID-19 patients and 72 matched controls). Median time from COVID-19 symptoms to PAT assessment was 9.5 and 101.5 days in groups 1 and 2, respectively. LnRHI was significantly lower in group 2 compared to both group 1 and controls (0.53 ± 0.23 group 2 vs. 0.72 ± 0.26 group 1, p = 0.0043; and 0.79 ± 0.23 in group 3, p < 0.0001). In addition, within group 1, it was observed a markedly decrease in LnRHI from acute COVID-19 to post infection stage (0.73 ± 0.23 vs. 0.42 ± 0.26, p = 0.0042).
CONCLUSIONS
This study suggests a deleterious effect of SARS-CoV-2 infection on systemic vascular endothelial function. These findings open new venues to investigate the clinical implication and prognostic role of vascular endothelial dysfunction in COVID-19 patients and post-COVID syndrome using non-invasive techniques.

Identifiants

pubmed: 34706286
pii: S0167-5273(21)01694-6
doi: 10.1016/j.ijcard.2021.10.140
pmc: PMC8542397
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

153-155

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Références

Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Eur Heart J. 2020 Sep 1;41(32):3038-3044
pubmed: 32882706
BMJ. 2021 Mar 31;372:n693
pubmed: 33789877
J Vis Exp. 2010 Oct 15;(44):
pubmed: 20972417
Eur Heart J. 2010 May;31(9):1142-8
pubmed: 20181680
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Angew Chem Int Ed Engl. 1999 Jul 12;38(13-14):1870-1880
pubmed: 34182659
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377

Auteurs

Hernan Mejia-Renteria (H)

Hospital Clínico San Carlos, IDISSC and Universidad Complutense de Madrid, Madrid, Spain. Electronic address: hmejiarenteria@gmail.com.

Alejandro Travieso (A)

Hospital Clínico San Carlos, IDISSC and Universidad Complutense de Madrid, Madrid, Spain.

Adam Sagir (A)

Bar-Ilan University, Faculty of Medicine, Safed, Israel.

Eduardo Martínez-Gómez (E)

Hospital Clínico San Carlos, IDISSC and Universidad Complutense de Madrid, Madrid, Spain.

Angela Carrascosa-Granada (A)

Hospital Clínico San Carlos, IDISSC and Universidad Complutense de Madrid, Madrid, Spain.

Takumi Toya (T)

Mayo Clinic, Rochester, MN, United States.

Iván J Núñez-Gil (IJ)

Hospital Clínico San Carlos, IDISSC and Universidad Complutense de Madrid, Madrid, Spain.

Vicente Estrada (V)

Hospital Clínico San Carlos, IDISSC and Universidad Complutense de Madrid, Madrid, Spain.

Amir Lerman (A)

Mayo Clinic, Rochester, MN, United States.

Javier Escaned (J)

Hospital Clínico San Carlos, IDISSC and Universidad Complutense de Madrid, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH